Clinical perspective on targeted alpha therapy using 225Ac.
Ilhan Lim1,2,3
1Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75 Nowon-ro, Gongneung dong, Nowon-gu, Seoul, 01812, Republic of Korea. ilhan@kcch.re.kr.
Annals of Nuclear Medicine
|October 9, 2025
Summary
Astatine-225 targeted alpha therapy shows promise for treating prostate cancer and neuroendocrine tumors with high efficacy and low toxicity. Further clinical research is needed to establish this advanced cancer treatment as a standard therapy.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiotherapy
Background:
- Targeted alpha therapy using Astatine-225 (225Ac) offers high linear energy transfer (LET) and short particle range.
- This approach has shown significant therapeutic benefits with minimal side effects in treating specific cancers.
Purpose of the Study:
- To review current research on 225Ac targeted alpha therapy for prostate cancer and neuroendocrine tumors.
- To explore advancements in protocols and expanded applications of this therapy for various cancers.
Main Methods:
- Literature review of studies on 225Ac targeted alpha therapy.
- Analysis of research focusing on treatment protocols and clinical outcomes.
Main Results:
- 225Ac therapy demonstrates outstanding therapeutic effects and minimal adverse effects in patients with prostate cancer and neuroendocrine tumors.
- Research efforts are enhancing therapeutic outcomes and expanding applications to other tumor types.
Conclusions:
- 225Ac targeted alpha therapy is a highly effective treatment for certain cancers.
- Additional clinical research is necessary to integrate 225Ac therapy into standard clinical practice.
